Successful Use of Targeted HIF‐2α Inhibition in EPAS1‐Mutated Congenital Erythrocytosis

Documenti analoghi

• Heterozygous TCF3‐related disease presenting as X‐linked agammaglobulinemia mimicry in a male toddler with B‐cell aplasia, agammaglobulinemia, and severe neutropenia
  di: Laura M. Bou‐Maroun, et al.
  Pubblicazione: (2024)
• Successful Management of Refractory Congenital Hemangioma With Sirolimus in a Neonate
  di: Yanyu Hou, et al.
  Pubblicazione: (2025)
• X‐Linked Sideroblastic Anemia Caused by ALAS2 Intron 1 Mutation Successfully Treated by Allogenic Hematopoietic Stem Cell Transplant
  di: Shurui Du, et al.
  Pubblicazione: (2026)
• Successful Use of Maribavir for Secondary CMV Prophylaxis in a Pediatric HSCT Patient
  di: Joshua Broadman, et al.
  Pubblicazione: (2025)
• MEK Inhibition With Trametinib for the treatment of MAP2K1‐Mutated Rosai–Dorfman–Destombes Disease Arising from the Nasopharynx in a Paediatric Patient
  di: Claire Cuerden, et al.
  Pubblicazione: (2025)